Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cerilliant
Farmers Insurance
US Department of Justice
AstraZeneca
Chinese Patent Office
Argus Health
Julphar
Covington

Generated: June 18, 2018

DrugPatentWatch Database Preview

ZEBETA Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Zebeta, and when can generic versions of Zebeta launch?

Zebeta is a drug marketed by Teva Womens and is included in one NDA.

The generic ingredient in ZEBETA is bisoprolol fumarate. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bisoprolol fumarate profile page.
Summary for ZEBETA
Drug patent expirations by year for ZEBETA
Medical Subject Heading (MeSH) Categories for ZEBETA
Synonyms for ZEBETA
(.+/-.)-1-[[.alpha.-(2-Isopropoxyethoxy)-p-tolyl]oxy]-3-(isopropylamino)-2-propanol
(+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
(RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol
[2-hydroxy-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propyl](propan-2-yl)amine
1-(4-((2-isopropoxyethoxy)methyl)phenoxy)-3-(isopropylamino)propan-2-ol
1-(4-[(2-Isopropoxyethoxy)methyl]phenoxy)-3-(isopropylamino)-2-propanol #
1-(propan-2-ylamino)-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propan-2-ol
1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol
1-[(1-methylethyl)amino]-3-({4-[({2-[(1-methylethyl)oxy]ethyl}oxy)methyl]phenyl}oxy)propan-2-ol
1-[4-(2-isopropoxyethoxymethyl)phenoxy]-3-(isopropylamino)propan-2-ol
1-[ISOPROPYLAMINO]-3-[ISOPROPOXYETHOXYMETHYLPHENOXY]-2-PROPANOL
1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)-2-propanol
1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol
2-Propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-
2-Propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)-
2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-
2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-, (.+/-.)-
3-(4-{[2-(methylethoxy)ethoxy]methyl}phenoxy)-1-[(methylethyl)amino]propan-2-o l
66722-44-9
722B449
AB0008008
AB00514681
AB00514681_09
AB00514681_10
AB00514681-08
ABP000339
AC-18540
AC1L1DLQ
AK326211
AKOS005110983
AN-38456
API0005144
ARONIS24082
AX8117415
BB 0262613
BBL023591
BC213835
BCP9000418
BCPP000332
BDBM25751
Bisocor
BISOPROLOL
Bisoprolol - from tablet donated by Watson -
Bisoprolol (JAN/USAN/INN)
Bisoprolol (USAN/INN)
Bisoprolol [USAN:BAN:INN]
Bisoprolol [USAN:INN:BAN]
Bisoprolol fumarate
Bisoprolol fumerate
Bisoprolol hemifumarate
Bisoprolol, analytical standard
Bisoprolol/
Bisoprololum
Bisoprololum [Latin]
BPBio1_000373
BSPBio_000339
C06852
C18H31NO4
Cardicor
CB0208
CHEBI:3127
CHEMBL645
CL 297,939
CL 297939
CL-297939
Concor
Concor (TN)
Concore (TN)
CTK8E3176
D02342
D0K3ZR
DB00612
Detensiel
DTXSID6022682
Emconcor
Emcor
EMD 33 512
EMD-33-512
EMD-33512
Euradal
FT-0655754
GTPL7129
HSDB 8316
I01-7040
Isoten
K094
KB-217442
KM1031
L000133
LS-122509
MCULE-4376025366
MFCD00865795
MolPort-005-937-320
Monocor
Monocor (TN)
NCGC00024868-02
NCGC00024868-03
NCGC00024868-04
NCGC00024868-05
NCGC00024868-06
NCGC00024868-08
OR019375
Prestwick0_000330
Prestwick1_000330
Prestwick2_000330
Prestwick3_000330
Q-200728
SBB065120
SBI-0206894.P001
SCHEMBL20960
Soloc
Soprol
SPBio_002260
STL355996
TR-022536
VHYCDWMUTMEGQY-UHFFFAOYSA-N
Zebeta (TN)

US Patents and Regulatory Information for ZEBETA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Womens ZEBETA bisoprolol fumarate TABLET;ORAL 019982-002 Jul 31, 1992 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Teva Womens ZEBETA bisoprolol fumarate TABLET;ORAL 019982-001 Jul 31, 1992 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for ZEBETA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Womens ZEBETA bisoprolol fumarate TABLET;ORAL 019982-002 Jul 31, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Teva Womens ZEBETA bisoprolol fumarate TABLET;ORAL 019982-001 Jul 31, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Citi
Moodys
Mallinckrodt
Chubb
AstraZeneca
Boehringer Ingelheim
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.